Cipla's Global Expansion in Biologics and Biosimilars with Kemwell Biopharma
Published: 11 Mar 2026
Author: Precedence Research
The pharmaceutical company Cipla, based in Mumbai, announced its partnership with Kemwell Biopharma through a joint venture to strengthen its position in the growing biologics and biosimilars market. The joint venture agreement was signed on March 2, 2026, with plans to create a new company in India. Cipla will hold a 60% stake in this venture, while Kemwell will own the remaining 40%.
Initially, both firms will invest up to ₹10 crore in the new company, according to their shareholdings. Once established, Cipla will purchase 6,000 equity shares priced at ₹10 each at par, amounting to ₹60,000.
A New Push for Global Biologics in Development and Manufacturing
The joint venture's goal is to develop, produce, and market biologic products for global markets. Its operations will include applying for and obtaining regulatory licenses, as well as importing, exporting, and outsourcing biologics-related activities, as noted by Cipla in a filing with the BSE.
According to Precedence Research, the UTI Drugs Market size accounted for USD 5.06 billion in 2025 and is predicted to increase from USD 5.34 billion in 2026 to approximately USD 8.65 billion by 2035, expanding at a CAGR of 5.50% from 2026 to 2035 due to the urgent need for cost effective treatment for chronic diseases, including cancer and autoimmune disorders and increasing aging population.
Kemwell functions as a biologics contract development and manufacturing organization (CDMO) in Asia, offering extensive services to international biopharma clients. Its Bengaluru facility, which is FDA-certified, has a bioreactor capacity of 5,000 liters, sterile fill-finish lines, and state-of-the-art laboratories for developing protein therapeutics. The organization supports both commercial manufacturing and research and development, along with clinical programs for innovative biologics and biosimilars. Cipla stated that this deal does not involve any related-party transactions and does not require any specific governmental or regulatory approvals at this moment. This strategic decision is a response to the rising global demand for biosimilars and advanced therapies.
A recent report by Precedence Research highlights that the UTI Drugs market is benefiting from increasing R&D investments, advanced manufacturing, a favorable regulatory environment, and the rapid growth of the monoclonal antibodies sector.